\n\nDate<\/b><\/p><\/td> | \nTotal number of shares composing the share capital<\/b><\/p><\/td> | \nTotal number of voting rights (1) (2)<\/sup><\/b><\/p><\/td><\/tr>\n\n\nTheoretical voting rights<\/i><\/b><\/p><\/td> | \nExercisable voting rights<\/i><\/b><\/p><\/td><\/tr>\n\n\n22 mai 2026<\/p><\/td> | \n16 114 656<\/p><\/td> | \n30 846 644<\/p><\/td> | \n30 814 120<\/p><\/td><\/tr>\n<\/table> \n(1) The theoretical voting rights are calculated on the basis of all shares to which voting rights are attached, including shares deprived of voting rights.<\/i><\/p> \n(2) In accordance with the resolutions dated March 23, 2022, double voting rights are granted to all fully paid-up shares for which a registered holding in the name of the same shareholder for at least two years has been evidenced, as from March 23, 2022.<\/i><\/p> \nAbout ABL Diagnostics (ABLD)<\/b><\/p> \nABL Diagnostics (ABLD) is an international company that specializes in innovative molecular biology tests and global solutions for its customers:<\/p> \n- \nMolecular polymerase chain reaction (PCR) detection \u2013 UltraGene, and<\/li>\n
- \nGenotyping by DNA sequencing \u2013 DeepChek\u00ae.<\/li>\n<\/ul>
\nABL Diagnostics markets its entire product range globally through its own sales team and a network of exclusive distributors active on all continents. ABL Diagnostics' customers are academic clinical pathology laboratories, private reference laboratories and researchers willing to implement innovative and robust microbiological content in constant expansion.<\/p> \nABL Diagnostics has been marketing the products and services of its sister company CDL Pharma since the second half of 2025 through an intra-group strategy agreement.<\/p> \nAn expanding portfolio of microbiology products:<\/b><\/p>\n- \nHIV \u2013 Drug resistance testing, including a whole genome kit.<\/li>\n
- \nSARS-CoV-2, Tuberculosis, Hepatitis B and C \u2013 Advanced Detection Solutions.<\/li>\n
- \nMicrobiome and taxonomy \u2013 16s\/18s RNA-based analyses.<\/li>\n
- \nOther viral and bacterial targets \u2013 Comprehensive molecular assays.<\/li>\n<\/ul>
\nIntegrated Solutions<\/b><\/p>\n- \nReal-time syndromic PCR tests<\/li>\n
- \nNadis\u00ae \u2013 Patient Medical Record used in more than 200 hospitals in France for the management of HIV and hepatitis.<\/li>\n
- \nMediaChek\u00ae \u2013 Clinical Sample Collection Kits.<\/li>\n<\/ul>
\nABL Diagnostics, headquartered in Woippy, is a public limited company listed on compartment B of the regulated market of Euronext in Paris (Euronext: ABLD \u2013 ISIN: FR001400AHX6). These molecular biology products generate recurring revenues and cover one of the largest portfolios of applications in microbiology.<\/p> \nSoci\u00e9t\u00e9 anonyme au capital de 1 611 465,60 euros\nHeadquarter : 72C route de Thionville - 57140 WOIPPY\n552 064 933 R.C.S. METZ<\/p> Contacts<\/b> \nABL Diagnostics SA<\/b>Soci\u00e9t\u00e9 anonyme au capital de 1 611 465,60 euros\nHeadquarters : 72C route de Thionville - 57140 WOIPPY\n552 064 933 R.C.S. METZ<\/p> \nTel : +33 (0)7 83 64 68 50\nEmail : info@abldiagnostics.com<\/a>https:\/\/www.abldiagnostics.com\/<\/a><\/p>","protected":false},"excerpt":{"rendered":"(Articles L. 233-8, II of the French Commercial Code and 223-16 of the AMF General Regulation)WOIPPY, France–(BUSINESS WIRE)–Regulatory News:
\nABL Diagnostics (Paris:ABLD)<\/p>\n Date
\nTotal number of shares composing the share capital
\nTotal number of voti…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-18630","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/18630","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=18630"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/18630\/revisions"}],"predecessor-version":[{"id":18631,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/18630\/revisions\/18631"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=18630"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=18630"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=18630"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}} | | |